Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment   tags : Covid-19    save search
COVID-19 Spurs Demand for Respiratory Care Devices, Driving Market Growth and Post-Pandemic Resilience in Respiratory Disease Treatment
Published: 2023-10-20 (Crawled : 19:00) - prnewswire.com
MDT | $80.38 -1.12% 0.0% 5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
IVCRQ | $0.0135 25.93% 110K twitter stocktwits trandingview |
n/a
 | Email alert Add to watchlist
TFX | $211.17 0.03% 1.34% 200K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
RMD | $183.78 -0.24% 0.0% 970K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
IVC | $0.6598 -19.67% 0 twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
MASI | $135.935 -0.74% -0.75% 230K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
RYLPF | $20.52 3.85% 110K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
covid-19 disease respiratory treatment care growth market
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases
Published: 2023-10-12 (Crawled : 20:00) - globenewswire.com
SXTP | $0.2506 -2.45% 130K twitter stocktwits trandingview |
n/a
 | | O: 9.16% H: 4.16% C: -2.23%
covid-19 malaria pharmaceuticals commercialization study tick-borne disease
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Published: 2023-09-12 (Crawled : 13:30) - globenewswire.com
SRNE | $0.015 -8.85% 56K twitter stocktwits trandingview |
Health Technology
 | | O: -3.62% H: 7.95% C: -8.1%
covid-19 treatment trial
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
Published: 2023-08-30 (Crawled : 12:00) - globenewswire.com
IFRX | $1.355 -0.37% -0.37% 71K twitter stocktwits trandingview |
Health Technology
 | | O: 6.95% H: 2.75% C: 2.75%
covid-19 vilobelimab review authorization treatment application
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov
Published: 2023-08-15 (Crawled : 12:00) - globenewswire.com
SXTP | $0.2506 -2.45% 130K twitter stocktwits trandingview |
n/a
 | | O: 0.0% H: 10.78% C: 7.23%
covid-19 treatment pharmaceuticals study
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
Published: 2023-07-14 (Crawled : 14:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M twitter stocktwits trandingview |
Health Technology
 | | O: -0.13% H: 1.34% C: 0.76%
covid-19 veklury fda renal treatment dialysis
Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19
Published: 2023-06-26 (Crawled : 13:20) - globenewswire.com
SRNE | $0.015 -8.85% 56K twitter stocktwits trandingview |
Health Technology
 | | O: 3.9% H: 0.0% C: -3.06%
sti-1558 covid-19 treatment trial
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
Published: 2023-06-21 (Crawled : 11:00) - globenewswire.com
IFRX | $1.355 -0.37% -0.37% 71K twitter stocktwits trandingview |
Health Technology
 | | O: 4.44% H: 0.0% C: -4.26%
covid-19 treatment commercial gohibic
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients
Published: 2023-05-16 (Crawled : 08:00) - prnewswire.com
IFRX | $1.355 -0.37% -0.37% 71K twitter stocktwits trandingview |
Health Technology
 | | O: 2.69% H: 1.61% C: -1.61%
covid-19 partnership treatment gohibic
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
Published: 2023-05-04 (Crawled : 12:00) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M twitter stocktwits trandingview |
Health Technology
 | | O: 0.06% H: 0.29% C: -0.7%
VERU | $1.325 3.92% 3.77% 1.5M twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 2.36% C: 0.0%
covid-19 fda sabizabulin treatment risk trial agreement
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
Published: 2023-04-25 (Crawled : 11:00) - ir.ateapharma.com
AVIR | $3.705 -0.67% -0.67% 200K twitter stocktwits trandingview |
Health Technology
 | | O: 0.62% H: 2.74% C: 1.86%
covid-19 fda granted treatment pharmaceuticals designation fast track designation
Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19
Published: 2023-04-20 (Crawled : 13:00) - biospace.com/
VTVT | $25.39 1.66% 1.63% 4.2K twitter stocktwits trandingview |
Health Technology
 | | O: -2.63% H: 1.89% C: 0.03%
covid-19 treatment azeliragon study
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
Published: 2023-04-04 (Crawled : 19:00) - globenewswire.com
IFRX | $1.355 -0.37% -0.37% 71K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
covid-19 fda authorization treatment
Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19
Published: 2023-04-03 (Crawled : 16:00) - biospace.com/
PRDS | $2.16 1.37% 2.4M twitter stocktwits trandingview |
Professional, Scientific, and T...
 | | O: -11.36% H: 28.21% C: 22.22%
covid-19 treatment trial results phase 2
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research
Published: 2023-03-14 (Crawled : 11:00) - globenewswire.com
AVIR | $3.705 -0.67% -0.67% 200K twitter stocktwits trandingview |
Health Technology
 | | O: 2.67% H: 8.67% C: 4.91%
covid-19 treatment hepatitis research conference bemnifosbuvir antiviral favorable international
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
Published: 2023-03-08 (Crawled : 12:00) - ir.ateapharma.com
AVIR | $3.705 -0.67% -0.67% 200K twitter stocktwits trandingview |
Health Technology
 | | O: 0.3% H: 2.98% C: 1.79%
covid-19 treatment hepatitis research conference bemnifosbuvir antiviral favorable international
Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19
Published: 2023-03-02 (Crawled : 08:00) - biospace.com/
BPTS | $10.15 3.36% 3.25% 3.7K twitter stocktwits trandingview |
Manufacturing
 | | O: 27.59% H: 22.0% C: 10.59%
bio101 covid-19 treatment service agreement
Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment
Published: 2023-02-28 (Crawled : 13:00) - globenewswire.com
SBFM | $0.9263 -23.45% -28.97% 10M twitter stocktwits trandingview |
Professional, Scientific, and T...
 | | O: 1.16% H: 4.34% C: -1.03%
covid-19 treatment biopharma license
Water and Wastewater Treatment Market for Food & Beverage Industry to Reach $78.35 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®
Published: 2023-02-21 (Crawled : 15:20) - prnewswire.com
GFL | $32.86 -1.05% 0.0% 910K twitter stocktwits trandingview |
Transportation
 | | O: -1.16% H: 0.64% C: -2.45%
DD | News | $73.96 0.22% 0.0% 1.5M twitter stocktwits trandingview |
Process Industries
 | | O: -1.01% H: 0.66% C: -1.83%
MMM | $92.02 -1.05% 0.0% 3.8M twitter stocktwits trandingview |
Producer Manufacturing
 | | O: -0.88% H: 0.36% C: -2.46%
covid-19 research water treatment trends report impact food market
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
Published: 2022-12-21 (Crawled : 13:20) - biospace.com/
IFRX | $1.355 -0.37% -0.37% 71K twitter stocktwits trandingview |
Health Technology
 | | O: 10.9% H: 17.09% C: 15.38%
covid-19 treatment agreement china
Gainers vs Losers
62% 38%

Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M twitter stocktwits trandingview |
Consumer Services
BOF | $1.99 70.09% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.51 6.03% 40.62% 1.7M twitter stocktwits trandingview |

LICN | $0.941 68.04% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.31 65.5% 39.58% 70M twitter stocktwits trandingview |
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M twitter stocktwits trandingview |
Technology Services
WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services
AIH | $0.45 12.5% 30.92% 320K twitter stocktwits trandingview |
Health Services
MULN | News | $3.78 38.46% 27.78% 13M twitter stocktwits trandingview |
Information
RILY | $29.86 37.48% 27.26% 12M twitter stocktwits trandingview |
Finance
Your saved searches
Save your searches and get alerts when important news are released.